バイオベンツの株価は 22.4%上昇 4Qの結果は予想を上回り JPMorganが評価を上げました Bioventus shares surge 22.4% as Q4 results beat estimates, with JPMorgan upgrading its rating.

医療機器会社ビオベンタスの株価は市場予想を上回る4Qの純損失と収益の上昇を報告した後に,市場前取引で22.4%上昇した. Medical device company Bioventus saw its shares rise by 22.4% in pre-market trading after reporting a narrower net loss and higher revenues for Q4, beating market estimates. 同社は2025年度の調整後1株当たり0.64ドルから0.68ドルと,分析者の予想を上回る5億6000万から5億7000万ドルの純売上を予測している. The company projects FY 2025 adjusted earnings per share of $0.64 to $0.68 and net sales of $560 million to $570 million, both above analyst expectations. さらにJPMモーガンはバイオベンツの評価を"中性"に上げ,価格の目標を1.3ドルに増やした. Additionally, JPMorgan raised Bioventus' rating to "neutral" and increased its price target to $13.00.